Everpar Advisors LLC Makes New Investment in Eli Lilly and Company (NYSE:LLY)

Everpar Advisors LLC purchased a new position in shares of Eli Lilly and Company (NYSE:LLY) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 3,165 shares of the company’s stock, valued at approximately $1,845,000. Eli Lilly and Company accounts for approximately 0.9% of Everpar Advisors LLC’s investment portfolio, making the stock its 18th biggest position.

Several other institutional investors also recently bought and sold shares of the company. Lewis Asset Management LLC purchased a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $688,000. Semus Wealth Partners LLC boosted its position in shares of Eli Lilly and Company by 13.2% during the 4th quarter. Semus Wealth Partners LLC now owns 1,976 shares of the company’s stock worth $1,152,000 after purchasing an additional 231 shares in the last quarter. Leavell Investment Management Inc. boosted its position in shares of Eli Lilly and Company by 3.2% during the 4th quarter. Leavell Investment Management Inc. now owns 5,726 shares of the company’s stock worth $3,338,000 after purchasing an additional 176 shares in the last quarter. Camelot Portfolios LLC purchased a new position in shares of Eli Lilly and Company in the 4th quarter valued at about $870,000. Finally, GAM Holding AG increased its holdings in shares of Eli Lilly and Company by 5.9% in the 4th quarter. GAM Holding AG now owns 15,046 shares of the company’s stock valued at $8,771,000 after purchasing an additional 833 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Down 2.8 %

NYSE LLY opened at $734.97 on Monday. The company has a market cap of $698.52 billion, a P/E ratio of 108.24, a P/E/G ratio of 1.46 and a beta of 0.37. Eli Lilly and Company has a 12 month low of $419.80 and a 12 month high of $800.78. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 0.73. The company has a 50-day moving average of $761.06 and a 200-day moving average of $672.28.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Tuesday, April 30th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.53 by $0.05. The firm had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. Eli Lilly and Company’s revenue for the quarter was up 26.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.62 earnings per share. As a group, equities analysts predict that Eli Lilly and Company will post 13.82 earnings per share for the current year.

Analyst Ratings Changes

LLY has been the topic of several recent analyst reports. Barclays upped their target price on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 7th. Citigroup lifted their price objective on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a report on Tuesday, April 2nd. Morgan Stanley upped their target price on Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a report on Friday, February 16th. Truist Financial lifted their price target on Eli Lilly and Company from $850.00 to $892.00 and gave the stock a “buy” rating in a research note on Wednesday, May 1st. Finally, Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $757.95.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.